U.S. Disability Rates Have Risen Sharply Since Rollout of mRNA COVID-19 Shots
The number of Americans reporting a disability has risen sharply since the rollout of mRNA COVID-19 shots in early 2021, reaching a record high of 37.03 million people aged 16 and older in July 2026, according to the latest data from the U.S. Bureau of Labor Statistics (BLS).1 In February 2021, two months after the […]
mRNA, Spike Proteins Persist in the Human Body for More Than 3.5 Years After COVID-19 Shots
A newly published case report in Medical Research Archives found that vaccine-derived synthetic mRNA, spike protein and plasmid DNA sequences persisted in the blood and tissue of a 55-year-old man more than three years after his last Pfizer mRNA COVID-19 shot, with some components detected beyond the 3.5-year mark. The case report, published July 1, […]
Medical School Enrollment at Record High as Physician Shortage Looms
Medical schools in the United States saw the highest number of student enrollments on record in 2025, according to new data from the Association of American Medical Colleges (AAMC). The AAMC reported that medical schools enrolled 100,723 students for the 2025–26 academic year, up 1.3 percent from the prior year, marking a rebound after a […]
COVID-19 Shots Associated with Neuropsychiatric Disorders
A 2025 study published in the International Journal of Innovative Research in Medical Science examined whether mRNA COVID-19 shots are linked to neuropsychiatric conditions, raising questions about their potential to damage the brain and mental health. The researchers, most of which are affiliated with The Wellness Company and the McCullough Foundation, note that the mRNA […]
FDA Revokes EUA Status for COVID-19 Shots
The U.S. Department of Health and Human Services (DHHS) has revoked emergency use authorization (EUA) for the COVID-19 shots. The federal government had relied on the EUA status to justify release of the COVID-19 biologicals in December 2020 for public distribution without full licensure by the FDA.1 On Aug. 27, 2025, DHHS Secretary Robert F. […]
FDA Approves Novavax’s COVID-19 Vaccine With Restrictions
On May 16, 2025, the U.S. Food and Drug Administration (FDA) approved licensure of Novavax, Inc.’s Nuvaxovid protein-based COVID-19 vaccine, which has been available in the United States under Emergency Use Authorization (EUA) since July 2022.1 The decision for a full licensure was postponed while the new agency leadership under the current administration conducted a […]